- Home
- PCQ vs RCEL Comparison
PCQ vs RCEL Comparison
Compare PCQ & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCQ
- RCEL
- Stock Information
- Founded
- PCQ 2001
- RCEL N/A
- Country
- PCQ United States
- RCEL United States
- Employees
- PCQ N/A
- RCEL N/A
- Industry
- PCQ Investment Managers
- RCEL Medical/Dental Instruments
- Sector
- PCQ Finance
- RCEL Health Care
- Exchange
- PCQ Nasdaq
- RCEL Nasdaq
- Market Cap
- PCQ 156.8M
- RCEL 158.1M
- IPO Year
- PCQ N/A
- RCEL N/A
- Fundamental
- Price
- PCQ $8.32
- RCEL $5.16
- Analyst Decision
- PCQ
- RCEL Strong Buy
- Analyst Count
- PCQ 0
- RCEL 4
- Target Price
- PCQ N/A
- RCEL $16.50
- AVG Volume (30 Days)
- PCQ 69.6K
- RCEL 257.2K
- Earning Date
- PCQ 01-01-0001
- RCEL 08-07-2025
- Dividend Yield
- PCQ 4.63%
- RCEL N/A
- EPS Growth
- PCQ N/A
- RCEL N/A
- EPS
- PCQ N/A
- RCEL N/A
- Revenue
- PCQ N/A
- RCEL $71,661,000.00
- Revenue This Year
- PCQ N/A
- RCEL $57.16
- Revenue Next Year
- PCQ N/A
- RCEL $36.69
- P/E Ratio
- PCQ N/A
- RCEL N/A
- Revenue Growth
- PCQ N/A
- RCEL 41.35
- 52 Week Low
- PCQ $8.19
- RCEL $4.71
- 52 Week High
- PCQ $10.50
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- PCQ 40.07
- RCEL 41.82
- Support Level
- PCQ $8.24
- RCEL $5.59
- Resistance Level
- PCQ $8.37
- RCEL $6.15
- Average True Range (ATR)
- PCQ 0.08
- RCEL 0.43
- MACD
- PCQ -0.01
- RCEL -0.02
- Stochastic Oscillator
- PCQ 20.00
- RCEL 9.85
About PCQ PIMCO California Municipal Income Fund
PIMCO California Municipal Income Fund is a closed-end management investment company. It seeks to provide current income exempt from federal and California income tax. The fund makes investments in different sectors such as healthcare, property, education, Natural Gas, and others.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.